Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vernex
- Development stage
- Preclinical
- Lead developer
- Regenics
- Administration
- Topical
01
Overview
Vernex (REG320) is a medical device developed by Regenics for the treatment of wounds, including burns and chronic wounds. It is formulated as a hydrogel wound spray incorporating HTX, a proprietary bioactive extract derived from salmon roe. The product is designed to facilitate wound healing by providing a moist environment and potentially leveraging the regenerative properties of the salmon roe-derived components. As of the current pipeline information, Vernex is in the preclinical stage of development.
- Brand names
- Vernex
Beyond the preview
Go deeper on Vernex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vernex.